Compare EXK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | VERA |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2004 | 2021 |
| Metric | EXK | VERA |
|---|---|---|
| Price | $8.33 | $42.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $13.94 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 7.0M | 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.59 | N/A |
| Revenue Next Year | $17.61 | $472.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $19.07 |
| 52 Week High | $15.15 | $56.05 |
| Indicator | EXK | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 71.97 |
| Support Level | $7.12 | $40.87 |
| Resistance Level | $8.36 | $42.77 |
| Average True Range (ATR) | 0.50 | 1.94 |
| MACD | -0.02 | 1.09 |
| Stochastic Oscillator | 39.78 | 89.55 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.